Unraveling Alzheimer’s Disease: Genes, Neurotransmitters, and Spiritual Challenges

QUESTION

1) Identify the risk genes for Alzheimer’s disease. What are the deterministic genes? 2) What neurotransmitter is the primary target of the drug therapies for Alzheimer’s disease? How is that neurotransmitter affected by the drugs? 3) Given what you know about the symptoms of Alzheimer’s disease, how could it create challenges for a person’s expression of faith and relationship with God?

ANSWER

Unraveling Alzheimer’s Disease: Genes, Neurotransmitters, and Spiritual Challenges

Alzheimer’s disease, a devastating neurodegenerative disorder, has captured the attention of researchers, clinicians, and society at large due to its profound impact on cognitive and emotional functioning. This essay delves into the multifaceted aspects of Alzheimer’s disease, including genetic determinants, neurotransmitter involvement, and the potential spiritual challenges faced by individuals afflicted by this condition.

Genetic Determinants of Alzheimer’s Disease: Alzheimer’s disease is influenced by various genetic factors, with risk genes and deterministic genes playing distinct roles. Risk genes, such as apolipoprotein E (APOE), increase the likelihood of developing the disease but do not guarantee its onset. Carriers of the APOE ε4 allele, for instance, are at a higher risk compared to those with other alleles. Deterministic genes, on the other hand, are rare and more directly associated with the disease’s development. Mutations in genes like APP, PSEN1, and PSEN2 lead to early-onset familial Alzheimer’s disease, characterized by early and aggressive symptoms.

Neurotransmitter and Drug Therapies

The primary target of drug therapies for Alzheimer’s disease is the neurotransmitter acetylcholine. A hallmark of the disease is the loss of cholinergic neurons, which severely impacts memory and cognitive functions. Drugs called cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, work by inhibiting the breakdown of acetylcholine, thereby increasing its availability in the brain. These drugs help alleviate cognitive symptoms and enhance neurotransmitter signaling within the depleted cholinergic pathways.

Alzheimer’s Disease and Spiritual Challenges

Alzheimer’s disease poses substantial challenges for individuals’ expression of faith and their relationship with God. The progressive deterioration of cognitive functions can result in the impairment of religious practices, rituals, and engagement with spiritual communities. Individuals may struggle to remember prayers, religious texts, and the significance of spiritual events. As the disease advances, the inability to participate in faith-related activities may lead to feelings of isolation, frustration, and a sense of detachment from their spiritual identity.

Furthermore, Alzheimer’s disease can disrupt the deep-rooted spiritual beliefs and understanding of the world. The cognitive decline may affect individuals’ capacity to process complex spiritual concepts, leading to confusion, doubt, and a sense of spiritual disconnect. This can create internal conflict, questioning, and emotional distress for individuals who once found solace and purpose in their faith.

Conclusion

Alzheimer’s disease is a complex neurological condition that intertwines genetic predisposition, neurotransmitter dysfunction, and profound psychological and emotional challenges. The genetic underpinnings, especially risk and deterministic genes, shape susceptibility to the disease. Neurotransmitter-targeting drug therapies aim to alleviate cognitive symptoms by enhancing acetylcholine availability. However, the disease’s progression can present unique spiritual challenges, potentially affecting an individual’s connection to faith, rituals, and religious communities. By acknowledging these multifaceted aspects, healthcare professionals and caregivers can provide holistic support to individuals with Alzheimer’s disease, addressing their cognitive, emotional, and spiritual needs.

References

Ballard, C., & Aarsland, D. (2018). Alzheimer’s disease. In Clinical Neurology and Neurosurgery (pp. 497-504). Elsevier.

Cummings, J., Aisen, P., DuBois, B., Frölich, L., Jack Jr, C. R., Jones, R. W., … & Scheltens, P. (2016). Drug development in Alzheimer’s disease: the path to 2025. Alzheimer’s Research & Therapy, 8(1), 39.

Klimova, B., Kuca, K., & Valis, M. (2018). Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a review. Drug design, development and therapy, 12, 3141.

Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., … & Soininen, H. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255-2263.